Bionano Genomics (BNGO)
(Delayed Data from NSDQ)
$0.96 USD
-0.03 (-2.75%)
Updated May 10, 2024 04:00 PM ET
After-Market: $0.94 -0.02 (-1.62%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Price, Consensus and EPS Surprise
BNGO 0.96 -0.03(-2.75%)
Will BNGO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BNGO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BNGO
Is AbCellera Biologics (ABCL) Outperforming Other Medical Stocks This Year?
After Plunging -23.84% in 4 Weeks, Here's Why the Trend Might Reverse for Bionano Genomics, Inc. (BNGO)
BNGO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate Viridian Therapeutics, Inc. (VRDN) to Report a Decline in Earnings: What to Look Out for
Will Bionano Genomics, Inc. (BNGO) Report Negative Q3 Earnings? What You Should Know
QIAGEN (QGEN) Extends the AI-Powered QCI Interpret Software
Other News for BNGO
The 3 Best Healthcare Stocks to Buy in May 2024
Bionano Announces Series of Major Advancements to its Suite of Computational Tools for Comprehensive Cancer Analysis
Bionano Genomics announces upgrades to cancer analysis suite
BioNano Genomics (BNGO) Gets a Buy from Scotiabank
Bionano stock climbs 7% in wake of Q1 report, software upgrades